ClearPoint Neuro, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
ClearPoint Neuro, Inc. (CLPT) reported Revenue from Contract with Customer, Excluding Assessed Tax of $10.88 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-03
- ClearPoint Neuro, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $10.88M, a 18.07% increase year-over-year.
- ClearPoint Neuro, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $12.13M, a 42.93% increase year-over-year.
- ClearPoint Neuro, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $10.41M, a 33.96% increase year-over-year.
- ClearPoint Neuro, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $8.86M, a 9.10% increase year-over-year.
- ClearPoint Neuro, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $36.97M, a 17.78% increase from fiscal 2024.
- ClearPoint Neuro, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $31.39M, a 31.04% increase from fiscal 2023.
- ClearPoint Neuro, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $23.95M, a 16.56% increase from fiscal 2022.
- ClearPoint Neuro, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $20.55M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.88M 10-Q · filed 2026-08-03 | $23.01M 10-Q · filed 2026-08-03 | $33.42M derived: sum of 3 quarters · filed 2026-08-03 | $42.28M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $12.13M 10-Q · filed 2026-05-13 | $22.54M derived: sum of 2 quarters · filed 2026-05-13 | $31.40M derived: sum of 3 quarters · filed 2026-05-13 | $40.61M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $10.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $19.27M derived: sum of 2 quarters · filed 2026-03-17 | $28.49M derived: sum of 3 quarters · filed 2026-08-03 | $36.97M 10-K · filed 2026-03-17 |
| 2025-09-30 | $8.86M 10-Q · filed 2025-11-06 | $18.08M derived: sum of 2 quarters · filed 2026-08-03 | $26.56M 10-Q · filed 2025-11-06 | $34.33M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $9.21M 10-Q · filed 2026-08-03 | $17.70M 10-Q · filed 2026-08-03 | $25.47M derived: sum of 3 quarters · filed 2026-08-03 | $33.59M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $8.48M 10-Q · filed 2026-05-13 | $16.26M derived: sum of 2 quarters · filed 2026-05-13 | $24.38M derived: sum of 3 quarters · filed 2026-05-13 | $32.24M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $7.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $15.89M derived: sum of 2 quarters · filed 2026-03-17 | $23.75M derived: sum of 3 quarters · filed 2026-03-17 | $31.39M 10-K · filed 2026-03-17 |
| 2024-09-30 | $8.12M 10-Q · filed 2025-11-06 | $15.98M derived: sum of 2 quarters · filed 2025-11-06 | $23.62M 10-Q · filed 2025-11-06 | $30.43M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $7.86M 10-Q · filed 2025-08-12 | $15.50M 10-Q · filed 2025-08-12 | $22.31M derived: sum of 3 quarters · filed 2025-08-12 | $28.07M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $7.64M 10-Q · filed 2025-05-13 | $14.45M derived: sum of 2 quarters · filed 2025-05-13 | $20.21M derived: sum of 3 quarters · filed 2025-05-13 | $26.16M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $6.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $12.57M derived: sum of 2 quarters · filed 2025-02-26 | $18.52M derived: sum of 3 quarters · filed 2025-02-26 | $23.95M 10-K · filed 2025-02-26 |
| 2023-09-30 | $5.76M 10-Q · filed 2024-11-07 | $11.71M derived: sum of 2 quarters · filed 2024-11-07 | $17.14M 10-Q · filed 2024-11-07 | $22.32M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $5.95M 10-Q · filed 2024-08-07 | $11.38M 10-Q · filed 2024-08-07 | $16.56M derived: sum of 3 quarters · filed 2024-08-07 | $21.70M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $5.43M 10-Q · filed 2024-05-07 | $10.61M derived: sum of 2 quarters · filed 2024-05-07 | $15.75M derived: sum of 3 quarters · filed 2024-05-07 | $20.95M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $5.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $10.32M derived: sum of 2 quarters · filed 2024-03-12 | $15.52M derived: sum of 3 quarters · filed 2024-03-12 | $20.55M 10-K · filed 2024-03-12 |
| 2022-09-30 | $5.15M 10-Q · filed 2023-11-09 | $10.35M derived: sum of 2 quarters · filed 2023-11-09 | $15.38M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $5.20M 10-Q · filed 2023-08-08 | $10.23M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $5.03M 10-Q · filed 2023-05-11 | |||
| 2021-09-30 | $4.57M 10-Q · filed 2022-11-08 | $12.02M 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| NeuroPace Inc (NPCE) | United States | $0.480B | -28.52 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |
| CERUS CORP (CERS) | United States | $0.525B | -86.40 |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |